Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew J Colombo

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|March 21, 2008
Complement factor H-binding protein, a putative virulence determinant of Borrelia hermsii, is an antigenic target for protective B1b lymphocytesMatthew J Colombo, Kishore R Alugupalli
Infection and Immunity|June 30, 2010
T-cell-independent immune responses do not require CXC ligand 13-mediated B1 cell migrationMatthew J Colombo, Guizhi Sun, Kishore R Alugupalli
Immunologic Research|December 6, 2011
B1b lymphocyte-derived antibodies control Borrelia hermsii independent of Fcα/μ receptor and in the absence of host cell contactMatthew J Colombo, David Abraham, Akira Shibuya, et al.
Dermatology and Therapy|June 22, 2024
Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc AnalysisApril W Armstrong, Sang Hee Park, Vardhaman Patel, et al.
Annals of the New York Academy of Sciences|April 25, 2015
B cells generated by B-1 development can progress to chronic lymphocytic leukemiaKyoko Hayakawa, Anthony M Formica, Matthew J Colombo, et al.
Dermatology and Therapy|May 30, 2025
Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal SymptomsJoseph F Merola, Philip J Mease, April W Armstrong, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 6, 2025
Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.
JAMA Dermatology|November 27, 2024
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical TrialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Journal of Immunology (Baltimore, Md. : 1950)|March 21, 2008
Complement factor H-binding protein, a putative virulence determinant of Borrelia hermsii, is an antigenic target for protective B1b lymphocytesMatthew J Colombo, Kishore R Alugupalli
Infection and Immunity|June 30, 2010
T-cell-independent immune responses do not require CXC ligand 13-mediated B1 cell migrationMatthew J Colombo, Guizhi Sun, Kishore R Alugupalli
Immunologic Research|December 6, 2011
B1b lymphocyte-derived antibodies control Borrelia hermsii independent of Fcα/μ receptor and in the absence of host cell contactMatthew J Colombo, David Abraham, Akira Shibuya, et al.
Dermatology and Therapy|June 22, 2024
Cumulative Benefit Over 52 Weeks With Deucravacitinib Versus Apremilast in Moderate to Severe Plaque Psoriasis: POETYK PSO-1 Post Hoc AnalysisApril W Armstrong, Sang Hee Park, Vardhaman Patel, et al.
Annals of the New York Academy of Sciences|April 25, 2015
B cells generated by B-1 development can progress to chronic lymphocytic leukemiaKyoko Hayakawa, Anthony M Formica, Matthew J Colombo, et al.
Dermatology and Therapy|May 30, 2025
Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal SymptomsJoseph F Merola, Philip J Mease, April W Armstrong, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|March 6, 2025
Deucravacitinib in plaque psoriasis: Four-year safety and efficacy results from the Phase 3 POETYK PSO-1, PSO-2 and long-term extension trialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.
JAMA Dermatology|November 27, 2024
Safety and Efficacy of Deucravacitinib in Moderate to Severe Plaque Psoriasis for Up to 3 Years: An Open-Label Extension of Randomized Clinical TrialsApril W Armstrong, Mark Lebwohl, Richard B Warren, et al.
Dermatology and Therapy|January 13, 2022
Deucravacitinib in Moderate to Severe Psoriasis: Clinical and Quality-of-Life Outcomes in a Phase 2 TrialDiamant Thaçi, Bruce Strober, Kenneth B Gordon, et al.
Pageof 1